Tech Company Financing Transactions

Sirius Therapeutics Funding Round

BioTrack Capital, Creacion Ventures and Hankang Capital participated in a $50 million Series B funding round for Sirius Therapeutics. The round was announced on 5/10/2025.

Transaction Overview

Announced On
5/10/2025
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to advance clinical development of its new siRNA therapeutics for cardiometabolic disorders and the growth of its new RNA delivery technologies.

Company Information

Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
11760 Sorrento Valley Road
San Diego, CA 92121
USA
Email Address
Overview
Sirius is an innovative biotech company developing novel RNAi therapies for global markets. We are dedicated to providing solutions for physicians and patients to manage cardiovascular diseases. Our aim is to be a leading developer of RNAi therapeutics for the management of chronic diseases. Sirius established an innovation, research and development center in the United States and a translational center in China to address unmet patient needs in chronic disease. Leveraging RNAi technology, we offer a portfolio of solutions for patients to change the future of cardiovascular disease.
Profile
Sirius Therapeutics LinkedIn Company Profile
Social Media
Sirius Therapeutics Company Twitter Account
Company News
Sirius Therapeutics News
Facebook
Sirius Therapeutics on Facebook
YouTube
Sirius Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Qunsheng Ji
  Qunsheng Ji LinkedIn Profile  Qunsheng Ji Twitter Account  Qunsheng Ji News  Qunsheng Ji on Facebook
Chief Medical Officer
Patrick Yue
  Patrick Yue LinkedIn Profile  Patrick Yue Twitter Account  Patrick Yue News  Patrick Yue on Facebook
Chief Scientific Officer
Curt Bradshaw
  Curt Bradshaw LinkedIn Profile  Curt Bradshaw Twitter Account  Curt Bradshaw News  Curt Bradshaw on Facebook
Vice President
David Li
  David Li LinkedIn Profile  David Li Twitter Account  David Li News  David Li on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/10/2025: Infinite Uptime venture capital transaction
Next: 5/10/2025: Foundation Alloy venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to record every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary